PARTNERS
Meet Our Network of Experts
Based in the UK, NeoVac is pioneering the next generation of RNA delivery with their advanced LipTx™ LNP 2.0 platform. They bring proprietary, highly tunable ionizable lipids that consistently achieve exceptional encapsulation efficiencies exceeding 90%. By pairing these with pre-optimized formulation kits, NeoVac eliminates early-stage guesswork, ensuring highly predictable, consistent, and reproducible RNA delivery from day one.
Spun out from Japan’s prestigious RIKEN research institute, TAGCyx Biotechnologies designs highly functional, customized oligonucleotide therapeutics using their proprietary Xenoligo® platform. Their scientific team specializes in expanding the genetic alphabet with unique unnatural base pairs to engineer high-affinity aptamers for targeted therapeutic applications. Partnering with TAGCyx allows development teams to incorporate next-generation nucleic acid candidates into their pipelines with unmatched molecular precision.
Born as a high-tech spinout from Slovenia’s largest research institution, Infinite Biotech bridges the frontier of physics, biology, and engineering with their paradigm-breaking InFiniteDT® digital-twin platform. They deliver advanced, mechanism-based cellular monitoring and multi-year disease predictions without the use of animal testing. By translating complex sub-cellular material interactions into highly predictable data, Infinite Biotech provides the predictive biology tools needed to confidently screen materials, map modes of action, and validate therapeutic efficacy at the earliest stages of development.
Operating at the intersection of academia and industry since 2009, Slovenian biotech company COBIK delivers cutting-edge solutions for challenging bioprocess workflows, scale-up, and non-GMP manufacturing.
Their deep expertise spans the development of plasmid DNA, proteins, VLPs, and viral vectors. By combining rigorous research with a proven track record of international collaborations, COBIK provides the robust process foundations and expert project management needed to transition complex biotherapeutics smoothly toward clinical manufacturing.